Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Slides:

Advertisements

Similar presentations

Fructose & Diabetes Go to to download these slides for your presentations.

Advertisements

Remote Monitoring Systems for Self-Managing Type 2 Diabetes: A Systematic Review Hayat Mushcab * 1, George Kernohan 1,2, PhD, Suzanne Martin 1,2, PhD *

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.

NATIONAL CENTER FOR CASE STUDY TEACHING IN SCIENCE Up All Night:

Athena Philis-Tsimikas, MD The American Journal of Medicine

Fructose as a Driver of Diabetes: An Incomplete View of the Evidence

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Figure 1.Flowchart of the article-selection process.

(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated albumin (GA; %) and (D) plasma fructosamine (μmol/L) measured.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

Schematic of screening program for diabetes mellitus (DM) during acute myocardial infarction (AMI). Schematic of screening program for diabetes mellitus.

Mean and interquartile glucose values for (A) random blood glucose, (B) fastingplasma glucose, (C) HbA1c, (D) 1-hour OGTT, (E) 2-hour OGTT and (F)triglycerides.

Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients.

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

Glucose, insulin, and AGE levels during an OGC before and after RT

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Change in markers of glycometabolism and cardiovascular risk profile.

Glucose-lowering medication in type 2 diabetes: overall approach.

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

TXNIP and caspase-1 protein levels are increased in the adipose tissue of ob/ob mice. TXNIP and caspase-1 protein levels are increased in the adipose tissue.

Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.

Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.

Continuous associations

The underlying physiological basis of the HOMA model.

Continuous associations

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

A1C (A) and serum glycated albumin (GA) (B) levels in 47 pregnant women (study 1) divided according to gestational period into group I (21–24 weeks; n.

Effect of age, sex, race/ethnicity, and obesity on the relation of glycemic measures to Si and AIR. In linear regression models with Si as the dependent.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Relationship between changes in mean fat cell volume and insulin sensitivity (M values) after gastric bypass of obese women. Relationship between changes.

Effect of empagliflozin on efficacy parameters at week 18.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Glycemic control and body weight over 52 weeks.

Difference in average school grades between offspring born to women with type 1 diabetes and the matched control children, by maternal third trimester.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Distribution of daily frequency of BGM

Western blot analysis of plasma proteins from two-dimensional gel electrophoresis. Western blot analysis of plasma proteins from two-dimensional gel electrophoresis.

Incidences of transitions between glycemic states by 25-OHD level.

Postoperative blood glucose levels and total insulin requirement.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

Effects of PCSK7 rs genotype and CHO diets on changes and reversion in fasting insulin levels and HOMA-IR during the 2-year intervention in white.

© The Author(s) Published by Science and Education Publishing.

Differences in the values of HbA1c variables between the retinopathy-positive and retinopathy-negative groups at year 20. Differences in the values of.

A: Detection of insulin aspart and insulin lispro by the Iso-insulin ELISA method. A: Detection of insulin aspart and insulin lispro by the Iso-insulin.

Risk of mortality in patients with diabetes and ESRD

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

The ADA research program supports research across the broad spectrum of diabetes types and research topic areas (proportions of 2011 allocations in dollars).

Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Cumulative mean numbers of confirmed (plasma glucose ≤3

A, Number of published pediatric complementary medicine (CM) systematic reviews (SRs) from 1966 to –2001 SR data are from Moher D, Soeken K,

Presentation transcript:

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c and glycated albumin]). Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c and glycated albumin]). Electronic searches of Cochrane Library, EMBASE and MEDLINE databases were supplemented by manual searches of the references of included trials. DM 1, type 1 diabetes; DM 2, type 2 diabetes; DM 1/2, both type 1 and type 2 diabetes. Adrian I. Cozma et al. Dia Care 2012;35:1611-1620 ©2012 by American Diabetes Association